Articles from Treatment.com AI Inc.

Vancouver, BC, July 16, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) and its wholly owned digital health platform and marketplace, Rocket Doctor, are providing a scalable response to Canada’s emergency department crisis with a data-backed diversion program. The program uses smart triage, provider infrastructure, and AI-enabled care to safely keep appropriate patients with low-acuity healthcare concerns out of overcrowded hospitals, while getting them the comprehensive out-patient care that they need, faster.

Backed by $1 million in funding from the CVS Health Foundation, the pilot initiative offers free, virtual health screenings to support aging with confidence, care, and convenience

Treatment.com AI completed the acquisition of Rocket Doctor, aligning AI-powered clinical intelligence with a proven virtual care delivery platform.‏Rocket Doctor patient volume grew 112% in Alberta year-over-year, with over 36,000 patients seen in 2024 and physician adoption growing 218%.‏New partnerships launched in California and Canada, including with Central California Alliance for Health, a ~450,000 member managed care plan and Melanoma Canada, a National organization.‏Medical Education Suite deployed at University of Minnesota, delivering scalable AI-driven clinical training and potential 40% cost savings.Rocket Doctor named Top Clinical Innovator by the American Telemedicine Association and invited to speak at Harvard Medical School and AARP’s AgeTech Accelerator. Vancouver, BC, July 08, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc.‏‏ (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) and its wholly owned digital health platform and marketplace, ‏‏Rocket Doctor‏‏, are pleased to share a series of achievements following the completion of their previously announced acquisition. Now operating under a unified vision, the two organizations have gained traction across product deployment, patient growth, national partnerships, and public recognition.‏‏The quarter began with the finalization of Treatment’s acquisition of ‏‏Rocket‏‏ Doctor‏‏, marking a pivotal milestone in the company’s mission to combine a proprietary AI knowledge engine with real-world virtual care delivery. This unified offering creates the potential for smarter, faster, and safer care, powered by the Global Library of Medicine (GLM), AI triage tools, and Rocket Doctor’s scalable proprietary electronic medical record and digital health platform, all designed by and for practicing physicians.‏‏Following the acquisition, Rocket Doctor experienced a 112% year-over-year increase in patient volume in Alberta, with 36,779 patients seen over the past 12 months. To date, more than 71,000 Albertans have accessed care through the platform, 35% of whom live in communities with fewer than 25,000 residents, underscoring the platform’s vital role in underserved areas. Physician adoption has grown by 218%, rising from 22 active physicians last year to 70 this year, enabling Rocket Doctor to scale rapidly in response to growing demand.‏‏Meanwhile, Treatment.com AI advanced its commitment to next-generation clinical education with the launch of its new generation of the ‏‏Medical Education Suite (MES)‏‏. Deployed at the University of Minnesota Medical School, the platform featured new AI-simulated patients to assess 240 third-year students during their OSCE exams, enabling both virtual and live testing at scale. According to estimates from Claudio Violato, Associate Dean of the School of Medicine, the solution has the potential to reduce exam administration costs by approximately 40%, while also lowering faculty workload.‏‏Rocket Doctor also secured new partnerships in both the U.S. and Canada. In California, the company ‏‏launched a virtual care program‏‏ with Central California Alliance for Health, a Medi-Cal managed care plan serving approximately 450,000 members. The program enables patients to access urgent, primary, and specialty care from Rocket Doctor’s physician network.‏‏In Canada, Rocket Doctor ‏‏partnered with Melanoma Canada‏‏ to expand access to follow-up care for high-risk skin cancer patients in Ontario, Alberta, and British Columbia, supporting earlier intervention and continuity of care in one of the country’s most prevalent cancer categories.‏‏In recognition of its innovation and clinical impact, Rocket Doctor was named ‏‏Top Clinical Innovator by the American Telemedicine Association‏‏ at the NEXUS2025 conference. The award highlights Rocket Doctor’s physician-led virtual care model and its ability to deliver high-quality care at scale.‏‏Rocket Doctor was also selected to participate in several high-profile accelerators and thought leadership programs. The company was welcomed into the UC Berkeley Health Engine Accelerator, a competitive, non-dilutive program for healthtech founders. Dr. William Cherniak, CEO and Founder of Rocket Doctor, was invited to speak at Harvard Medical School by Halle Tecco to share insights with medical and business students on building accessible, AI-supported virtual care platforms. He also joined the 2025 AARP AgeTech Accelerator, where he showcased Rocket Doctor’s work in supporting aging, Medicaid, and Medicare populations across the U.S.‏‏The company’s growing profile was further amplified on the national stage. Dr. Hamza and Dr. Cherniak were invited to ‏‏ring the opening bell‏‏ at the Canadian Securities Exchange, followed by a joint appearance on the ‏‏CSE’s official podcast‏‏ discussing the future of AI and virtual care in North America. Dr. Cherniak also ‏‏spoke at the CSE Summit ‏‏on‏‏ Responsible Investment (SoRI) ‏‏in Kelowna, BC, engaging directly with investors on the evolution of healthcare delivery models.‏‏Adding to the quarter’s momentum, Dr. Cherniak, alongside other leading physicians, co-authored a peer-reviewed research paper titled ‏‏“‏‏Sociodemographic Variation in Use of and Preferences for Digital Technologies Among Patients in Primary Care.‏‏”‏‏ The study offers valuable insight into patient behaviour and the role of digital tools in improving health equity.‏‏“The past few months have been transformational for both Rocket Doctor and Treatment.com AI,” said Dr. William Cherniak. “We’ve aligned behind a shared vision and are now executing across multiple fronts - from clinical training to specialist care - while helping patients and providers reimagine what modern care can look like.”‏‏“We’re proud of the momentum achieved so far,” said Dr. Essam Hamza, CEO of Treatment.com AI. “Our focus remains on combining physician-led care, proven and tested AI tools and strong partnerships to improve healthcare delivery.”‏‏About Treatment.com AI Inc.‏Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine - the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.‏‏Learn more at‏‏ ‏‏www.treatment.com‏‏ or contact info@treatment.com‏‏ .‏‏About Rocket Doctor Inc.‏‏Rocket Doctor is a technology-driven digital health platform and marketplace that is breaking down obstacles that limit access to quality, comprehensive and cost-effective healthcare. Our proprietary software equips doctors with the tools to run practices in virtual and hybridized in-person/virtual models of care, enabling them to provide tailored care to patients in rural and Northern communities across Canada and on Medicaid in the United States. Leveraging large language models, AI/ML and wireless medical devices, Rocket Doctor is bridging the healthcare divide, connecting patients to equitable and accessible virtual healthcare services regardless of age, location, or financial status‏‏. ‏‏Visit‏‏ ‏‏www.rocketdoctor.ca‏‏ or contact ‏‏media@rocketdoctor.io‏‏.‏‏FOR ADDITIONAL INFORMATION, CONTACT:‏ ‎‏Dr. Essam Hamza, CEO‏ ‎‏Email: ehamza@treatment.com‏ ‎‏Media inquiries: media@treatment.com‏ ‎‏Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955‏‏Cautionary Statement‏‏This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.‏‏The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.‏

Updated AI-powered OSCE platform launched to enhance medical education delivery and evaluation.Successfully deployed at University of Minnesota with 240 students and potential of ~40% cost savings.Features AI-simulated patients and real-time scoring to support faster, accurate and objective assessments.Preliminary results presented at 2025 AAMC annual GIR meeting in Minneapolis. VANCOUVER, BC, June 11, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce that it has released its latest version of the Medical Education Suite (MES). The University of Minnesota Medical School has successfully completed a live deployment of Treatment.com AI’s new Medical Education Suite (MES), an AI-powered clinical skills assessment platform designed to support medical schools in delivering scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs).‏‏The deployment, conducted with over 240 third-year medical students, marked the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM), a clinician-built medical knowledge engine. The exams ran with complete technical reliability during deployment, as well as integrating seamlessly into the school’s existing OSCE workflow.‏‏“Our goal is to support medical schools by applying our clinical experience and AI expertise to real educational challenges.” stated Dr. Kevin Peterson, Founder and Chief Medical Officer of Treatment.com AI. “The Medical Education Suite reflects years of development in diagnostic reasoning and knowledge engineering. By introducing structured, AI-simulated patients alongside live simulated patients, and offering objective real-time scoring, we’re helping students build stronger clinical skills in the classroom and giving educators the trusted healthcare education software needed to teach and assess clinical content and behavioral approaches to complex clinical problems with confidence.”‏‏The MES is a scalable platform designed to reduce administrative and faculty time, improve objectivity, increase evaluation consistency, and provide a robust digital infrastructure to support both live and AI-simulated formats. The focus of the platform is to help enhance the clinical skills of our next generation of healthcare professionals. By incorporating curated AI-generated cases and the supportive services provided by Treatment, the system enables: Significant reduction in faculty preparation and administrative workload.Real-time scoring that aligns directly with clinical learning objectives.Objective student evaluations with built-in educational and remediation support.Alignment with LCME standards.Secure and scalable exam delivery on campus or remotely.The University of Minnesota has calculated their Administrative cost savings ~ 40%. ‏“Partnering with Treatment.com AI gave us the opportunity to explore how clinically governed AI can strengthen the way we assess and support student learning. The MES allowed us to deliver a high-stakes OSCE at scale, while ensuring consistent, objective evaluation aligned with our academic standards. The MES represents a meaningful step forward in the evolution of medical education.” said Professor Claudio Violato, Assistant Dean, University of Minnesota Medical School. “We look forward to sharing our findings.”‏‏The MES combines AI-simulated patients with automated feedback, helping faculty assess diagnostic and management reasoning, clinical prioritization, and documentation quality, all mapped to learning objectives. Early feedback suggests that the platform enhances the student learning experience and strengthens the reliability of OSCE results.‏‏ Preliminary results of the accuracy and precision of the GLM as applied in the MES platform were presented at the AAMC’s 2025 Group on Information Resources meeting. Prof. Violato, Dr. Peterson, and their respective teams are preparing further scientific publications detailing the methodology, deployment, and outcomes of the UMN program.‏‏Treatment.com AI is engaging with a wide variety of other schools, with the goal to extend the MES offering across North America, the UK, and to other international OSCE markets.‏‏About Treatment.com AI Inc.‏‏Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. ‏‏Learn more at: ‏‏ ‏‏www.treatment.com‏‏ or contact ‏‏info@treatment.com‏‏.‏‏About University of Minnesota Medical School‏‏Founded in 1888, the University of Minnesota Medical School is one of the nation’s largest, with three campuses in Minneapolis, Duluth, and St. Cloud. It enrolls first- and second-year students at Duluth and St. Cloud, and carries clinical training at the Twin Cities campus and affiliated hospitals. The school educates future physicians through MD, graduate, undergraduate, and continuing professional development programs, supported by over 3,000 faculty members and 20+ research centers and institutes. Its core mission is to improve health through exceptional education, compassionate patient care, and leading-edge biomedical research, particularly focusing on primary care, specialty medicine, rural communities, and American Indian/Alaska Native populations. The school is nationally recognized for its NIH-funded research (ranked #21 overall, #2 among public medical schools) and emphasizes interprofessional, community-based training while promoting equity and access across diverse populations.‏‏Learn more at: ‏‏msdean@umn.edu‏‏ ‏‏FOR ADDITIONAL INFORMATION, CONTACT:‏ ‎‏Dr. Essam Hamza, CEO – Treatment.com AI Inc.‏ ‎‏Email: ‏‏ehamza@treatment.com‏‏Media inquiries: ‏‏media@‏‏treatment.com‏‏Sales: ‏‏richard.atkins@treatment.com‏‏ ‏ ‎‏Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955‏‏Cautionary Statement‏‏This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com AI believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.‏‏The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.‏

Updated AI-powered OSCE platform launched to enhance medical education delivery and evaluation.Successfully deployed at University of Minnesota with 240 students and potential of ~40% cost savings.Features AI-simulated patients and real-time scoring to support faster, accurate and objective assessments.Preliminary results presented at 2025 AAMC annual GIR meeting in Minneapolis. VANCOUVER, BC, June 11, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce that it has released its latest version of the Medical Education Suite (MES). The University of Minnesota Medical School has successfully completed a live deployment of Treatment.com AI’s new Medical Education Suite (MES), an AI-powered clinical skills assessment platform designed to support medical schools in delivering scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs).‏‏The deployment, conducted with over 240 third-year medical students, marked the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM), a clinician-built medical knowledge engine. The exams ran with complete technical reliability during deployment, as well as integrating seamlessly into the school’s existing OSCE workflow.‏‏“Our goal is to support medical schools by applying our clinical experience and AI expertise to real educational challenges.” stated Dr. Kevin Peterson, Founder and Chief Medical Officer of Treatment.com AI. “The Medical Education Suite reflects years of development in diagnostic reasoning and knowledge engineering. By introducing structured, AI-simulated patients alongside live simulated patients, and offering objective real-time scoring, we’re helping students build stronger clinical skills in the classroom and giving educators the trusted healthcare education software needed to teach and assess clinical content and behavioral approaches to complex clinical problems with confidence.”‏‏The MES is a scalable platform designed to reduce administrative and faculty time, improve objectivity, increase evaluation consistency, and provide a robust digital infrastructure to support both live and AI-simulated formats. The focus of the platform is to help enhance the clinical skills of our next generation of healthcare professionals. By incorporating curated AI-generated cases and the supportive services provided by Treatment, the system enables: Significant reduction in faculty preparation and administrative workload.Real-time scoring that aligns directly with clinical learning objectives.Objective student evaluations with built-in educational and remediation support.Alignment with LCME standards.Secure and scalable exam delivery on campus or remotely.The University of Minnesota has calculated their Administrative cost savings ~ 40%.‏ ‏“Partnering with Treatment.com AI gave us the opportunity to explore how clinically governed AI can strengthen the way we assess and support student learning. The MES allowed us to deliver a high-stakes OSCE at scale, while ensuring consistent, objective evaluation aligned with our academic standards. The MES represents a meaningful step forward in the evolution of medical education.” said Professor Claudio Violato, Assistant Dean, University of Minnesota Medical School. “We look forward to sharing our findings.”‏‏The MES combines AI-simulated patients with automated feedback, helping faculty assess diagnostic and management reasoning, clinical prioritization, and documentation quality, all mapped to learning objectives. Early feedback suggests that the platform enhances the student learning experience and strengthens the reliability of OSCE results.‏‏ Preliminary results of the accuracy and precision of the GLM as applied in the MES platform were presented at the AAMC’s 2025 Group on Information Resources meeting. Prof. Violato, Dr. Peterson, and their respective teams are preparing further scientific publications detailing the methodology, deployment, and outcomes of the UMN program.‏‏Treatment.com AI is engaging with a wide variety of other schools, with the goal to extend the MES offering across North America, the UK, and to other international OSCE markets.‏‏About Treatment.com AI Inc.‏‏Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. ‏‏Learn more at: ‏‏ ‏‏www.treatment.com‏‏ or contact ‏‏info@treatment.com‏‏.‏‏About University of Minnesota Medical School‏‏Founded in 1888, the University of Minnesota Medical School is one of the nation’s largest, with three campuses in Minneapolis, Duluth, and St. Cloud. It enrolls first- and second-year students at Duluth and St. Cloud, and carries clinical training at the Twin Cities campus and affiliated hospitals. The school educates future physicians through MD, graduate, undergraduate, and continuing professional development programs, supported by over 3,000 faculty members and 20+ research centers and institutes. Its core mission is to improve health through exceptional education, compassionate patient care, and leading-edge biomedical research, particularly focusing on primary care, specialty medicine, rural communities, and American Indian/Alaska Native populations. The school is nationally recognized for its NIH-funded research (ranked #21 overall, #2 among public medical schools) and emphasizes interprofessional, community-based training while promoting equity and access across diverse populations.‏‏Learn more at: ‏‏msdean@umn.edu‏‏ ‏‏FOR ADDITIONAL INFORMATION, CONTACT:‏ ‎‏Dr. Essam Hamza, CEO – Treatment.com AI Inc.‏ ‎‏Email: ‏‏ehamza@treatment.com‏‏Media inquiries: ‏‏media@‏‏treatment.com‏‏Sales: ‏‏richard.atkins@treatment.com‏‏ ‏ ‎‏Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955‏‏Cautionary Statement‏‏This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com AI believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.‏‏The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.‏

Partnership now live, with services available for eligible patients across Central California

Selection aims to accelerate Rocket Doctor’s mission to deliver accessible, tech-enabled care to underserved communities.

Selection aims to accelerate Rocket Doctor’s mission to deliver accessible, tech-enabled care to underserved communities.

From classrooms to conferences, Rocket Doctor earns national spotlight for transforming virtual care delivery

‎ New collaboration will connect patients flagged during mobile skin cancer screenings with Rocket Doctor physicians across Ontario, Alberta, and British Columbia

‎‎ New collaboration will connect patients flagged during mobile skin cancer screenings with Rocket Doctor physicians across Ontario, Alberta, and British Columbia

‏VANCOUVER, BC, May 15, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) and Rocket Doctor, its wholly owned online care platform, applaud United States Secretary of Health and Human Services, Robert F. Kennedy Jr., for his remarks during the House Appropriations Committee Budget Hearing yesterday, where he championed the potential role of telehealth and artificial intelligence in improving access to care.‏

Recognition highlights Rocket Doctor’s leadership in advancing physician-led virtual care models across North America

 

 

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) Announces Rocket Doctor’s Growth and Expansion in Alberta, Empowering Independent Physicians and Enhancing Patient Access to Care.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) Announces Rocket Doctor’s Growth and Expansion in Alberta, Empowering Independent Physicians and Enhancing Patient Access to Care.

Vancouver, British Columbia, March 13, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that further to its news releases dated February 27, 2025 and March 3, 2025, it has closed its previously announced brokered private placement under the Listed Issuer Financing Exemption (the “Offering”) with Ventum Capital Corp., (the “Underwriter”) who acted as underwriter pursuant to an underwriting agreement dated March 13, 2025 (the “Underwriting Agreement”).

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) Announces Rocket Doctor’s Approval as an In-Network Provider for New York Medicaid Strengthening Access to Virtual Healthcare Across the State and Collaboration with EngageWell.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) Announces Rocket Doctor’s Approval as an In-Network Provider for New York Medicaid Strengthening Access to Virtual Healthcare Across the State and Collaboration with EngageWell.

●Treatment.com AI announces expanded and updated MES new releases

●Treatment.com AI announces expanded and updated MES new releases

Treatment.com AI CEO, Dr. Essam Hamza, is to present live at 11:00 AM ET on Wednesday, October 9, 2024.

Treatment.com AI CEO, Dr. Essam Hamza, is to present live at 11:00 AM ET on Wednesday, October 9, 2024.

VANCOUVER, British Columbia, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to provide marketing updates and a general corporate update on its focus on the utilization of AI within the medical education sector.

VANCOUVER, British Columbia, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to provide marketing updates and a general corporate update on its focus on the utilization of AI within the medical education sector.

VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with SPRYT Limited (“SPRYT”). Both innovative AI healthcare organizations, SPRYT and Treatment are exploring complementary technology synergies, including Treatment’s proprietary Global Library of Medicine (“GLM”), to build new solutions designed to mitigate patient access challenges, administrative overheads for healthcare professionals and cost inefficiencies throughout our healthcare systems.

VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with SPRYT Limited (“SPRYT”). Both innovative AI healthcare organizations, SPRYT and Treatment are exploring complementary technology synergies, including Treatment’s proprietary Global Library of Medicine (“GLM”), to build new solutions designed to mitigate patient access challenges, administrative overheads for healthcare professionals and cost inefficiencies throughout our healthcare systems.

VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with the University Court of the University of Edinburgh (“University of Edinburgh”). The University of Edinburgh is looking to utilize Treatment’s proprietary Global Library of Medicine (“GLM”) to jointly build applications within the “SET4 Systems Engineering to Transform Transitions In Health and Social Care innovation initiative” (“SET4”).

VANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with the University Court of the University of Edinburgh (“University of Edinburgh”). The University of Edinburgh is looking to utilize Treatment’s proprietary Global Library of Medicine (“GLM”) to jointly build applications within the “SET4 Systems Engineering to Transform Transitions In Health and Social Care innovation initiative” (“SET4”).

VANCOUVER, British Columbia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights, endorses the forward thinking emanating from a recent event in Washington comprising 25 of the nation’s leading experts on the appropriate use of artificial intelligence (AI) within healthcare.

VANCOUVER, British Columbia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights, endorses the forward thinking emanating from a recent event in Washington comprising 25 of the nation’s leading experts on the appropriate use of artificial intelligence (AI) within healthcare.

VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is excited to announce a new solution, AI Pharmacy Assistant designed to support pharmacists. Pharmacists are playing an increasing role in the provision of clinical decision support services, given the increasing number of people without a GP and/or the time taken to book appointments.

VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is excited to announce a new solution, AI Pharmacy Assistant designed to support pharmacists. Pharmacists are playing an increasing role in the provision of clinical decision support services, given the increasing number of people without a GP and/or the time taken to book appointments.

●~800,000 warrants exercised since free trading was announced raising close to half a million dollars.

●~800,000 warrants exercised since free trading was announced raising close to half a million dollars.

●Positive Financial Update

●Positive Financial Update

VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with Health Care Services International Inc (o/a Novus Health). (“Novus Health”) to explore utilization of Treatment’s proprietary Global Library of Medicine (“GLM”) to further enhance Novus Health’s Health Risk Assessment programs.

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to announce the appointment of Richard Atkins as Chief Operating Officer and a member of the executive team.

VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is excited to announce one of the leading US medical schools has agreed to a contract renewal utilizing Treatment’s Medical Education Suite (“MES”).

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “ Company ” or “ Treatment ”) is excited to announce two new solutions, (1) AI Patient and (2) AI Doctor in a Pocket, to augment its Medical Education Suite (“ MES ”) designed to educate the next generation of healthcare providers.

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “ Company ” or “ Treatment ”) is excited to announce two new solutions, (1) AI Patient and (2) AI Doctor in a Pocket, to augment its Medical Education Suite (“ MES ”) designed to educate the next generation of healthcare providers.

VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with aiXplain, Inc. (“aiXplain”) to enable greater access to Treatment’s proprietary Global Library of Medicine (“GLM”) by contributing to aiXplain’s ever-growing dynamic Artificial Intelligence (AI) marketplace.

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) welcomes Prime Minister Justin Trudeau’s announcement on 7th April, 2024, that the federal government plans to fund $2.4 billion in its upcoming budget towards build capacity in Artificial Intelligence (AI) adoption.

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that the Company has received funding from The National Institute of Health (“NIH”) to develop a culturally sensitive AI approach for collecting family medical history.

VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that it’s AI medical information support platform was used in the “Objective Structured Clinical Examination” (“OSCE”), a standard clinical exam of diagnostic aptitude at medical and nursing schools, passing the exam with a 92% success rate.

Vancouver, British Columbia, March 14, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that, further to its news release dated February 16, 2024, it has closed a non-brokered private placement of 6,295,500 special warrants of the Company (each, a “Special Warrant”) at a price of $0.40 per Special Warrant, for aggregate gross proceeds of $2,518,200 and 975,000 units of the Company (each, a “Unit”) at a price of $0.40 per Unit, for aggregate gross proceeds of $390,000 (the “Offering”).

Vancouver, BC, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce the appointment of Mr. David Worner as Chief Financial Officer of the Company, effective February 5, 2024.